<DOC>
	<DOCNO>NCT00002269</DOCNO>
	<brief_summary>To evaluate ampligen two dosage level give twice weekly combination zidovudine ( AZT ) versus AZT alone individual HIV-related immune dysfunction define T4 count 100 300 cells/mm3 .</brief_summary>
	<brief_title>A Multicenter , Double-Blind , Controlled Study Evaluate Ampligen</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>poly ( I ) .poly ( c12 , U )</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV1 seropositivity . Absolute number T4 cell 100300 cells/mm3 . Given informed consent . Zidovudine ( AZT ) therapy 6 month prior study entry . At least one list HIVrelated clinical symptom opportunistic infection : weight loss &gt; 10 percent , unexplained diarrhea , unexplained intermittent fever , oral candidiasis &gt; 1 month , decrease Karnofsky , oral hairy leukoplakia , chronic fatigue . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Evidence AIDS . Intercurrent acute medical disorder . Concurrent Medication : Excluded : Chemotherapy Kaposi 's sarcoma ( KS ) . Aspirin . Nonsteroidal antiinflammatory drug . Patients follow exclude : Inability return treatment evaluation 12 month . Intercurrent acute medical disorder . Evidence AIDS . Receiving chemotherapy Kaposi 's sarcoma ( KS ) . Unwilling unable give inform consent . Required : Zidovudine ( AZT ) . Required least 6 month prior study entry : Zidovudine ( AZT ) . Active drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1991</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>ampligen</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>